Blood Res.  2017 Sep;52(3):221-224. 10.5045/br.2017.52.3.221.

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis

• Huh JY
• Seo S
• Suh C
• Huh J
• Yoon DH
• Kim JJ

• KMID: 2390987
• DOI: http://doi.org/10.5045/br.2017.52.3.221

Abstract

No abstract available.

MeSH Terms

Amyloidosis*
Heart*
Stem Cell Transplantation*
Stem Cells*

Figure

• 

  Fig. 1 Cardiac magnetic resonance image of the study patient at the time of diagnosis. The delayed enhancement image displays subendocardial enhancement at both the left and right ventricle walls (A). Pathology of the initial endomyocardial biopsy (B, C). Congored stain showing positivity for amyloid deposits. Under polarized light, amorphous materials showing an apple-green birefringence were evident (B). Immunohistochemical staining results: prealbumin (+); kappa chain (++); lambda chain (-); amyloid A (-) (C).

• 

  Fig. 2 Changes in the free light-chain profile and levels of brain natriuretic peptide in the study patient.Abbreviations: BNP, brain natriuretic peptide; dFLC, free light-chain difference.

Reference

1. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008; 143:369–373. PMID: 18691169.

2. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2006; 107:1227–1229. PMID: 16210334.

3. Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010; 90:905–911. PMID: 20733534.

4. Davis MK, Kale P, Liedtke M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015; 15:650–658. PMID: 25648766.

5. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998; 91:141–157. PMID: 9578896.

6. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004; 140:85–93. PMID: 14734330.

7. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997; 337:898–909. PMID: 9302305.

8. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983; 58:665–683. PMID: 6353084.

9. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant. 1999; 24:853–855. PMID: 10516696.

10. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30:989–995. PMID: 22331953.

11. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008; 27:823–829. PMID: 18656793.